Shares of Sun Pharmaceutical Industries surged nearly 2% after the company announced that it has received approval from the U.S. Food and Drug Administration (US FDA) for LEQSELVI (deuruxolitinib), an oral JAK inhibitor for the treatment of severe alopecia areata. As of 10:42 AM, the shares were trading 1.45% higher at ₹1,690.00 on the NSE.
Alopecia areata is an autoimmune disease that causes hair loss on the scalp, face, and sometimes other parts of the body. It affects around 700,000 people in the United States, with 300,000 cases considered severe. LEQSELVI works by interrupting the pathways believed to contribute to hair loss in severe cases of the disease.
The approval of LEQSELVI offers new hope to patients with severe alopecia areata, many of whom seek professional treatment only after being dissatisfied with the slow progress of existing therapies.
